anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: cosmetics; hygienic preparations for skin care. SUBSTANCE: cosmetic preparation in the form of gel contains aqueous-alcoholic extract of drug plants possessing tonic and/or vitaminizing, and/or clarifying, and/or bactericidal, and/or healing action; anolyte with content of calcium ions 0.7-1.4%, prepared by electrochemical way by treatment with solution of calcium chloride; and 0.5-3.0-% aqueous solution of low-esterified pectin. Proposed cosmetic preparation comprises the following drug plants in preset ratio: camomile, dog rose, aloe, ginseng, St. Johnswort, nettle, curled parsley, dogberry, and cucumber. The preparation has mild consistency, is easily applied on skin and suppresses growth of pathogenic microorganisms. EFFECT: improved effect. 2 cl, 4 ex
Stroke is the leading cause of death and disability worldwide. Given the increasing average lifespan worldwide, the incidence and prevalence of patients with stroke will dramatically increase in the future. One of the most frequent and devastating conditions after stroke is aphasia, which affects language production and comprehension. High-frequent intensive speech-and-language therapy is currently the treatment of choice in chronic aphasia. However, despite its general effectiveness, treatment effect sizes are only low to moderate. Thus, there is a pressing need to explore novel training-adjuvant therapies to enhance treatment efficacy. Moreover, very little is known about the neurobiology of treatment-induced recovery in chronic aphasia. This is the prerequisite to improve existing and/or develop new treatment paradigms.

Thus, in the present project we aim to assess whether the outcome of intensive language training can be enhanced by adjuvant non-invasive brain stimulation. We will be using anodal transcranial direct current stimulation (atDCS) that has previously been shown to enhance (a) language and motor learning in healthy subjects and (b) motor recovery in stroke patients. Specifically, in a longitudinal group comparison design, two matched groups of patients with chronic anomia will receive two weeks of intensive language training with or without atDCS. Treatment effects will be assessed immediately after the two week intervention period and several months after the end of the training. We will also use functional and structural magnetic resonance imaging (MRI) to elucidate language network changes in the two groups.
Proteinaceous polymers having repetitive units from naturally occurring structural proteins are employed as backbones for functionalities for crosslinking to provide strongly adherent tissue adhesive compositions for bonding together separated tissue, and for sealing or filling tissue defects by injecting the compositions into the defects. Particularly, block copolymers having repeating units of elastin and fibroin are employed having lysine substitutions in spaced apart units, where the amino group can be crosslinked using difunctional crosslinking agents such as glutaraldehyde, activated diolefins, diisocyanates, acid anhydrides or diamines. The protein polymer contains at least 40 weight percent of repetitive units of 3 to 30 amino acids, preferably 3 to 15 amino acids, of at least one naturally occurring structural protein and at least two amino acids containing a functional group capable of reacting with the crosslinking agent. The protein polymer generally has a molecular weight of at least about 30 kD and not more than 250 kD. A preferred protein polymer contains at least 70 weight percent of repetitive units of Gly-Ala-Gly-Ala-Gly-Ser and Gly-Val-Gly-Val-Pro, where in at least two units an amino acid is substituted with one of lysine or arginine, and the protein polymer has a lysine and arginine equivalent weight in the range of 1 to 20 kD and contains at least two amino acids having a functional group capable of reacting with at least one of aldehyde, isocyanate, thioisocyanate and activated carboxy. The protein polymer is produced by recombinant DNA technology, and a kit may be formed containing the crosslinking agent and protein polymer.
Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
The women in the control group received standard care, which in this context is opportunistic screening. Women in the control group had the possibility of asking for an appointment for mammography, if they wanted to do so. To ask for the appointment, women must complete different steps: 1) women have to ask for an appointment with a health professional in a primary health center; 2) a health professional has to prescribe a mammography, 3) then women ask for the appointment at the administrative office in the health center.
Post-traumatic stress disorder (PTSD), prevalent among Veterans, puts Veterans at increased risk for obesity and related conditions. Veterans with PTSD lose less weight in VA's MOVE! weight management program, due to PTSD symptoms that interfere with activity and healthy diet. In addition, many Veterans who receive evidence-based PTSD treatment remain symptomatic. A behavioral weight loss program that augments standard PTSD care and targets PTSD-related weight loss barriers called MOVE!+UP was piloted and iteratively refined among 44 overweight Veterans with PTSD, and is currently being tested in an RCT. However, not all Veterans will participate in group-based treatment and prior work on integrated tobacco cessation with individual psychotherapy was quite impactful, and was particularly well-suited for coordinating augmentative medication management using shared decision-making. As such, we propose to conduct an uncontrolled pilot of an intervention called I MOVE!+UP. It will integrate MOVE!+UP into individual evidence-based psychotherapy (i.e.., Cognitive Processing Therapy) for PTSD for up to 6 months, augmented with evidence-based psychiatric and weight management medication management coordination. If I MOVE!+UP is acceptable, feasible, and proof-of-concept outcomes demonstrate potential benefit to weight and PTSD outcomes, we will apply for large-scale funding to test it in an RCT. I MOVE!+UP integrated behavioral intervention will be led by a psychotherapist (social worker, psychologist, or trainee in those disciplines). Because this care will be delivered within the context of routine mental health care, patients will be offered the opportunity for individualized pharmacotherapy for weight loss and psychiatric symptom management as part of their care plan.
BACKGROUND: Endometriosis is often described as a progressive disease beginning with menarche and menstrual bleeding. However, this is controversial, as the origin of the disease remains unknown. The objective of this study was to investigate the association between the severity of endometriosis and age at initial diagnosis.
MATERIAL AND METHODS: This prospective multicenter cohort study included 964 patients, newly and histologically diagnosed with endometriosis during laparoscopic treatment. The main outcome measures were diagnostic lesions with staging according to rAFS (revised American Fertility Society) scores, intensity of pain based on VAS (Visual Analog Scale) scores and quality of life from SF-36 questionnaire results. Age was treated as a categorical variable. Univariate and multivariable analyses (linear and multinomial ordinal) were conducted taking into account two by two multiple comparisons. The results were expressed with effect sizes and 95 % confidence intervals.
MAIN FINDINGS: No significant association between age and rAFS stage was found (p = 0.053). The percentage of patients with a deep nodule ≥ 2 cm was respectively 20 %, 25 %, 21 %, 18 % and 9 % for patients aged ≤ 25, 26-30, 31-35, 36-40 and >40 years respectively (p = 0.005). For dysmenorrhea, 64 %, 61 %, 54 %, 51 % and 32 % of patients aged ≤25, 26-30, 31-35, 36-40 and >40 years respectively reported a VAS score of ≥7 (p ≤ 0.001).
CONCLUSION: Prospective data obtained in patients newly diagnosed with endometriosis, revealed that the rAFS score is not related to patient age, and that the percentage of patients with a nodule ≥ 2 cm and severe dysmenorrhea did not increase with age. These percentages were significantly lower in patients aged > 40.
Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
<P>PROBLEM TO BE SOLVED: To provide a method of reducing a metal oxide ion such as<SP>99m</SP>TcO<SB>4</SB><SP>-</SP>, which is usually reduced with a reducing agent, without using the reducing agent.  <P>SOLUTION: The metal oxide ion in a solution is reduced by removing an oxidizing species from the solution under radioactive rays without adding a reducing agent to the solution. The oxidizing species can be removed, for example, by sending an inert gas or nitrogen gas to the solution. It is preferable to remove the oxidizing species by bubbling the solution with a gas and venting the gas phase. When the solution contains a ligand for forming a complex, the complex of a metal oxide ion-reduced body is formed.  <P>COPYRIGHT: (C)2004,JPO
Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
Three undescribed (1-3) and nine known (4-12) platanosides were isolated and characterized from a bioactive extract of the May leaves of Platanus × acerifolia that initially showed inhibition against Staphylococcus aureus. Targeted compound mining was guided by an LC-MS/MS-based molecular ion networking (MoIN) strategy combined with conventional isolation procedures from a unique geographic location. The novel structures were mainly determined by 2D NMR and computational (NMR/ECD calculations) methods. Compound 1 is a rare acylated kaempferol rhamnoside possessing a truxinate unit. 6 (Z,E-platanoside) and 7 (E,E-platanoside) were confirmed to have remarkable inhibitory effects against both methicillin-resistant S. aureus (MIC: ≤ 16 μg/mL) and glycopeptide-resistant Enterococcus faecium (MIC: ≤ 1 μg/mL). These platanosides were subjected to docking analyses against FabI (enoyl-ACP reductase) and PBP1/2 (penicillin binding protein), both of which are pivotal enzymes governing bacterial growth but not found in the human host. The results showed that 6 and 7 displayed superior binding affinities towards FabI and PBP2. Moreover, surface plasmon resonance studies on the interaction of 1/7 and FabI revealed that 7 has a higher affinity (KD = 1.72 μM), which further supports the above in vitro data and is thus expected to be a novel anti-antibacterial drug lead.
During robot-assisted radical prostatectomy, pneumoperitoneum with Trendelenburg position is used. However, perioperative atelectasis and respiratory complications may occur with high incidence due to general anesthesia and carbon dioxide pneumoperitoneum. Intraoperative ventilatory strategy to address these issues include intraoperative recruitment maneuver and positive end-expiratory pressure (PEEP). Recently, individualized optimal PEEP with minimal driving pressure or maximal respiratory compliance was reported to reduce respiratory complications after general anesthesia. A recent version of general anesthesia ventilator provides a stepwise procedure of determining optimal PEEP by calculating respiratory compliance. We investigated whether the application of individualized optimal PEEP could reduce the incidence of atelectasis and respiratory complications after robot-assisted laparoscopic radical prostatectomy compared to uniform PEEP. We plan to determine the degree of immediate postoperative atelectasis by measuring the lung ultrasound score and compare the lung ultrasound score between groups.
This study will assess the safety, tolerability, pharmacodynamics and pharmacokinetics of JNJ-39588146 or placebo (which looks like the drug being studied but has no active ingredients) in patients with heart failure. This study is being conducted in two parts. Part 1 is a randomized (study drug will be assigned by chance), double-blind (neither the physician nor patient knows the identity of the assigned drug) study of 3 intravenous doses of JNJ-39588146 or placebo administered in 1-hr intervals (for a total of 3 hours) in 60 patients with heart failure. Part 2 is an extended infusion of JNJ-39588146 and placebo that will administer the highest tolerated dose from Part 1 for an additional 18 hours. The entire duration of the infusion could be as long as 21 hours. There is a 1 in 4 chance of getting placebo. The participation period is a maximum of 42 days, including a screening visit, a 2-day in-clinic period and two follow-up visits. For both parts of the study, patients will have a cardiac catheter in place to monitor heart function. Safety evaluations, which will include ECG (electrocardiograph, measuring the electrical currents in the heart), vital signs and monitoring of side-effects will be performed. Additionally, blood and urine samples will be collected for evaluation. Part 1: Patients will receive an intravenous (IV) solution of three different doses of JNJ-39588146 or placebo administered over 1 hour periods for a total of 3 hours. Part 2: Patients participating in the sub study will continue receiving an IV solution for 18 more hours for a total of up to 21 hours of administration.
OBJECTIVE: To study the clinicopathological characteristics of patients with synchronous medullary and papillary thyroid carcinomas.
METHODS: The clinical data of patients with medullary thyroid carcinoma (MTC) operated in our hospital (Department of Thyroid Surgery, China-Japan Union Hospital, Jilin University) from February 2009 to February 2023 were evaluated using an analytical review approach. They were divided into an observation group (patients with synchronous MTC and papillary thyroid carcinoma PTC) and a control group (simple MTC) according to whether the clinical data were associated with MTC, in order to compare the clinical features, pathological types, stage characteristics and molecular biology characteristics of the two groups and to investigate the follow-up of the two groups.
RESULTS: The study included 122 MTC, 30 with synchronous MTC/PTC and 92 simple MTC. When the data were compared, the sex ratio, preoperative calcitonin level, preoperative CEA level, presence of calcifications in the MTC lesions, surgical methods, number of MTC lesions, presence of nodular goitre and presence of thyroiditis were higher in the observation group than in the control group. There was a significant difference between the groups when the MTC lesion diameter was ≤1cm in terms of preoperative CEA value (P<0.05); when the MTC lesion diameter was >1cm, there was a statistical difference between the two groups in terms of preoperative Ctn value (P<0.05). Type III was significantly different from the simple group, while type IV was more similar to the simple group. The preoperative serum Ctn value was positively correlated with maximum tumour diameter in both groups, although the correlation was stronger in the easy group. Preoperative CEA was positively correlated with maximum tumour diameter in both groups, with a stronger correlation in the combination group. Preoperative Ctn and CEA were positively correlated with lymph node metastasis in the simple group, whereas there was no apparent correlation with lymph node metastasis in the combination group. The cut-off value of preoperative serum Ctn for cervical lymph node metastases in the simple group was 39.2pg/ml and for lateral cervical lymph node metastases 195.5pg/ml. The cut-off value of preoperative serum Ctn for cervical lymph node metastases in the combination group was 60.79pg/ml and for lateral cervical lymph node metastases 152.6pg/ml. In the simple group, prognosis was significantly worse in the progression group (P<0.001), with no statistical difference between the remission and stable groups. In the combination group, the prognosis of the progression and stable groups was significantly worse than that of the remission group (P<0.001), with no statistical difference between the progression and stable groups.
CONCLUSION: In patients with synchronous medullary and papillary thyroid carcinomas, preoperative Ctn and CEA levels, calcifications, solitary lesions, combined goitre or thyroiditis differ significantly from simple MTC. Therefore, clinical management should pay attention to the above factors and early risk screening should be performed to improve prognosis as much as possible.
Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
Provided is a homogeneous polysaccharide ESP-B4, method for producing the same and use thereof. The ESP-B4 is a polysaccharide monomer, which is isolated from the traditional Chinese medicine Ephedra sinica Stapf, Ephedra intermedia Schrenk et C. A. Mey, or Ephedra equisetina Bge. HPSEC-ELSD shows a single symmetrical peak. The chemical construction of ESP-B4 is an acidic heterosaccharide. It is composed of xylose, arabinose, glucose, rhamnose, mannose, galactose, glucuronic acid and galacturonic acid with a molar ratio of 1.0:4.5:1.0:2.0:5.5:1.5:50. The molecular weight of ESP-B4 is 2.37×107 Da, and the content of galacturonic acid was 75.2%. The application of ESP-B4 is significant activity against infectious acute lung injury, respiratory distress syndrome, asthma, pneumonia, trachea and bronchitis. Therefore, it can be used for severe infectious acute lung injury caused by SARS virus, influenza a virus, avian influenza virus. Meanwhile, ESP-B4 has few side effects, simple preparation method, and it is suitable for industrial production.
In patients who have failed under the three main classes of antiretroviral agents (NRTI, NNRTI and PI) and in whom the control of viral replication in the plasma has ultimately been achieved with enfuvirtide, the aim is to sustain this virological success for as long as possible to thus enable satisfactory immune reconstitution, avoid further accumulation of viral mutations conferring resistance to the drugs and protect the patient from the risk of opportunistic disease and death.

Indeed, enfuvirtide is the lead compound in the new class of antiretroviral drugs which inhibit the fusion of HIV-1 virus with its target cell. Its in vivo efficacy was demonstrated during the pivotal studies TORO 1 and 2. Despite its efficacy, maintaining long-term treatment with enfuvirtide is nonetheless difficult for patients because of the constraints related to twice-daily subcutaneous parenteral injections. Furthermore, these subcutaneous injections are associated with inflammatory reactions at the injection site in 98 per cent of patients, without any reduction in frequency or severity over time. It is thus critical for patients who are well controlled by enfuvirtide to be able to simplify their treatment by replacing enfuvirtide with another active compound taken by mouth, which would enable maintenance of the virological response and acceptable safety in patients who have usually failed under the three main classes of antiretroviral drugs. A new antiviral compound, viral integrase inhibitor called raltegravir, could be proposed instead of enfuvirtide.
FIELD: medicine. SUBSTANCE: invention proposes the biologically active addition consisting of cryopowders made of different sources of natural compounds, in part, vegetable and mineral raw. It has cryopowders of vegetable and/or berry, and/or fruit raw. and/or legumes, and/or vegetable green, and/or cereals, and/or their embryos, and/or algae, and/or plant medicinal raw, and/or mushrooms, and/or shell powders, and/or crustacean, reptile and/or mollusk armors and shells. Particle size of cryopowders is 10-800 mcm. Method of preparing the proposed biologically active addition involves treatment of preliminary prepared vegetable and mineral raw by grinding under normal or decreased pressure in the presence of cooling agent. Proposed biologically active addition uses the more broad spectrum of the parent vegetable and mineral raw containing different natural compounds. Invention can be used for development of cosmetic, hygiene and pharmacological agents. EFFECT: enhanced effectiveness of biologically active addition. 10 cl, 1 tbl
A system and method for delivering molecular iodine or any other substance into a pet's drinking water on a daily basis without exceeding the safe amount allowed for the pet. The present invention delivers a particular amount of molecular iodine into the pet water supply to achieve maximum benefit of I 2  to reduce or eliminate bad pet breath and minimize total iodine in the pet diet so that 20-40 μg/mL/Kg/day iodine is consumed for optimum thyroid health. The preferred method is to use a solution created by dissolving iodine crystals in absolute ethanol. The iodine will only be in solution as I 2  for a short time as it undergoes out gassing and hydrolysis at neutral pH. The present invention removes the iodine from the drinking water after the pet drinks. Therefore, during the day, pets will get no additional iodine—only fresh water from the water reservoir. Each enrolled pet is recognized by the system using an ID tag such as an RFID tag. This insures that, when there are multiple enrolled pets, each pet receives its specific dose, and only as often as is programmed. Vitamins, drugs and other substances can also be administered to pets using the present invention.
Compositions, methods of manufacture, methods of improving dietary health, kits, devices, and uses for plasma activated water are provided. Plasma activated water may be used for improving nitric oxide levels, improving health and/or reducing symptoms of cardiometabolic syndrome in a subject. Compositions and methods for improving nitric oxide levels in a subject disclosed herein comprise consumption of a composition comprising dietary nitrate contained in plasma activated water. The health benefits of consuming plasma activated water include lowering blood pressure, lowering intraocular pressure, decreasing LDL/TG levels, restoring nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation in nitric oxide deficient subjects. In addition, consumption of plasma activated water also improves oral health and reduces and/or prevents cancer burden. In an embodiment, plasma activated water may also benefit general health, as nitric oxide deficiencies correlate to numerous physiological aberrations, such as cancer.